Suzuki, Shinya http://orcid.org/0000-0002-4769-5925
,
Yamashita, Takeshi
Akao, Masaharu
Okumura, Ken
Funding for this research was provided by:
Bristol-Myers Squibb K.K. (monetary support)
Japan Agency for Medical Research and Development (15656344, JP17ek0210082)
Article History
Received: 4 March 2020
Accepted: 12 May 2020
First Online: 25 May 2020
Compliance with ethical standards
: Prior to the start of the main study, the investigators in charge received a review from the ethics committee of their main participating facility and acquired approval. Prior to enrollment, the contents of the study were explained to the patients using explanatory documents and consent documents, and written consent was obtained. If a patient withdrew consent during the observation period, all existing data collected from the patient were discarded. The study plan and its design were registered in the UMIN Clinical Trials Registry (UMIN000017895).
: SS received research funding from Daiichi-Sankyo and Mitsubishi-Tanabe. TY received lecture fees from Bristol-Myers Squibb, Daiichi-Sankyo, Bayer, Pfizer, Ono Pharmaceutical, and Toa Eiyo and research funding from Bayer and Daiichi Sankyo. MA received lecture fees from Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim, Bayer Healthcare, and Daiichi-Sankyo. KO received lecture fees from Daiichi-Sankyo, Boehringer Ingelheim, and Johnson and Johnson.